117 results on '"Moormann RJ"'
Search Results
2. Foot-and-mouth Disease Transmission in Africa: Implications for Control, a Review.
- Author
-
Tekleghiorghis T, Moormann RJ, Weerdmeester K, and Dekker A
- Subjects
- Africa, Southern epidemiology, Animal Husbandry, Animals, Animals, Wild, Buffaloes, Commerce, Foot-and-Mouth Disease prevention & control, Foot-and-Mouth Disease transmission, Foot-and-Mouth Disease Virus genetics, Transportation, Foot-and-Mouth Disease epidemiology
- Abstract
In Africa, for the control of foot-and-mouth disease (FMD), more information is needed on the spread of the disease at local, regional and inter-regional level. The aim of this review is to identify the role that animal husbandry, trade and wildlife have on the transmission of FMD and to provide a scientific basis for different FMD control measures in Africa. Review of literature, published reports and databases shows that there is more long distance spread of FMD virus serotypes within North, West, Central and East Africa than in southern Africa. In North, West, Central and East Africa migratory animal husbandry systems often related with search for grazing and water as well as trade are practiced to a greater extent than in southern Africa. In southern Africa, the role of African buffalo (Syncerus caffer) is more extensively studied than in the other parts of Africa, but based on the densities of African buffalo in Central and East Africa, one would assume that buffalo should also play a role in the epidemiology of FMD in this part of Africa. More sampling of buffalo is necessary in West, Central and East Africa. The genetic analysis of virus strains has proven to be valuable to increase our understanding in the spread of FMD in Africa. This review shows that there is a difference in FMD occurrence between southern Africa and the rest of the continent; this distinction is most likely based on differences in animal husbandry and trade systems. Insufficient data on FMD in wildlife outside southern Africa is limiting our understanding on the role wildlife plays in the transmission of FMD in the other buffalo inhabited areas of Africa., (© 2014 Blackwell Verlag GmbH.)
- Published
- 2016
- Full Text
- View/download PDF
3. Co-housing of Rift Valley Fever Virus Infected Lambs with Immunocompetent or Immunosuppressed Lambs Does Not Result in Virus Transmission.
- Author
-
Wichgers Schreur PJ, van Keulen L, Kant J, Oreshkova N, Moormann RJ, and Kortekaas J
- Abstract
Rift Valley fever virus (RVFV) is transmitted among susceptible animals by mosquito vectors. Although the virus can be isolated from nasal and oral swabs of infected animals and is known to be highly infectious when administered experimentally via oral or respiratory route, horizontal transmission of the virus is only sporadically reported in literature. We considered that immunosuppression resulting from stressful conditions in the field may increase the susceptibility to horizontally transmitted RVFV. Additionally, we reasoned that horizontal transmission may induce immune responses that could affect the susceptibility of contact-exposed animals to subsequent infection via mosquito vectors. To address these two hypotheses, viremic lambs were brought into contact with sentinel lambs. One group of sentinel lambs was treated with the immunosuppressive synthetic glucocorticosteroid dexamethasone and monitored for signs of disease and presence of virus in the blood and target organs. Another group of contact-exposed sentinel lambs remained untreated for three weeks and was subsequently challenged with RVFV. We found that none of the dexamethasone-treated contact-exposed lambs developed detectable viremia, antibody responses or significant increases in cytokine mRNA levels. Susceptibility of immunocompetent lambs to RVFV infection was not influenced by previous contact-exposure. Our results are discussed in light of previous findings.
- Published
- 2016
- Full Text
- View/download PDF
4. Vector independent transmission of the vector-borne bluetongue virus.
- Author
-
van der Sluijs MT, de Smit AJ, and Moormann RJ
- Subjects
- Animals, Bluetongue epidemiology, Bluetongue prevention & control, Bluetongue virus classification, Bluetongue virus isolation & purification, Cattle, Europe, Infectious Disease Transmission, Vertical, Sheep, Vaccination, Vaccines, Attenuated, Viral Vaccines immunology, Bluetongue transmission, Bluetongue virology, Bluetongue virus physiology, Disease Vectors
- Abstract
Bluetongue is an economically important disease of ruminants. The causative agent, Bluetongue virus (BTV), is mainly transmitted by insect vectors. This review focuses on vector-free BTV transmission, and its epizootic and economic consequences. Vector-free transmission can either be vertical, from dam to fetus, or horizontal via direct contract. For several BTV-serotypes, vertical (transplacental) transmission has been described, resulting in severe congenital malformations. Transplacental transmission had been mainly associated with live vaccine strains. Yet, the European BTV-8 strain demonstrated a high incidence of transplacental transmission in natural circumstances. The relevance of transplacental transmission for the epizootiology is considered limited, especially in enzootic areas. However, transplacental transmission can have a substantial economic impact due to the loss of progeny. Inactivated vaccines have demonstrated to prevent transplacental transmission. Vector-free horizontal transmission has also been demonstrated. Since direct horizontal transmission requires close contact of animals, it is considered only relevant for within-farm spreading of BTV. The genetic determinants which enable vector-free transmission are present in virus strains circulating in the field. More research into the genetic changes which enable vector-free transmission is essential to better evaluate the risks associated with outbreaks of new BTV serotypes and to design more appropriate control measures.
- Published
- 2016
- Full Text
- View/download PDF
5. Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.
- Author
-
Kortekaas J, Vloet RP, McAuley AJ, Shen X, Bosch BJ, de Vries L, Moormann RJ, and Bente DA
- Subjects
- Animals, Antibodies, Neutralizing, Disease Models, Animal, Drosophila genetics, Drosophila metabolism, Female, Glycoproteins chemistry, Glycoproteins immunology, Hemorrhagic Fever, Crimean immunology, Humans, Mice, Mice, Knockout, STAT1 Transcription Factor genetics, Vaccines, Subunit, Hemorrhagic Fever Virus, Crimean-Congo immunology, Hemorrhagic Fever, Crimean prevention & control, Vaccination, Viral Vaccines immunology
- Abstract
Crimean-Congo hemorrhagic fever virus is a tick-borne bunyavirus of the Nairovirus genus that causes hemorrhagic fever in humans with high case fatality. Here, we report the development of subunit vaccines and their efficacy in signal transducer and activator of transcription 1 (STAT1) knockout mice. Ectodomains of the structural glycoproteins Gn and Gc were produced using a Drosophila insect cell-based expression system. A single vaccination of STAT129 mice with adjuvanted Gn or Gc ectodomains induced neutralizing antibody responses, which were boosted by a second vaccination. Despite these antibody responses, mice were not protected from a CCHFV challenge infection. These results suggest that neutralizing antibodies against CCHFV do not correlate with protection of STAT1 knockout mice.
- Published
- 2015
- Full Text
- View/download PDF
6. Nonspreading Rift Valley Fever Virus Infection of Human Dendritic Cells Results in Downregulation of CD83 and Full Maturation of Bystander Cells.
- Author
-
Oreshkova N, Wichgers Schreur PJ, Spel L, Vloet RP, Moormann RJ, Boes M, and Kortekaas J
- Subjects
- Antigens, CD genetics, B7-1 Antigen genetics, B7-1 Antigen metabolism, Cell Differentiation, Cells, Cultured, Cytokines metabolism, Dendritic Cells immunology, Dendritic Cells metabolism, Down-Regulation, Gene Expression, Glyceraldehyde-3-Phosphate Dehydrogenases genetics, Glyceraldehyde-3-Phosphate Dehydrogenases metabolism, Host-Pathogen Interactions, Humans, Immunoglobulins genetics, Lipopolysaccharides pharmacology, Membrane Glycoproteins genetics, Proteasome Endopeptidase Complex metabolism, Proteolysis, Rift Valley Fever prevention & control, Rift Valley Fever virology, Vaccines, Attenuated immunology, Viral Vaccines immunology, Virus Replication, CD83 Antigen, Antigens, CD metabolism, Dendritic Cells virology, Immunoglobulins metabolism, Membrane Glycoproteins metabolism, Rift Valley Fever immunology, Rift Valley fever virus immunology
- Abstract
Vaccines based on nonspreading Rift Valley fever virus (NSR) induce strong humoral and robust cellular immune responses with pronounced Th1 polarisation. The present work was aimed to gain insight into the molecular basis of NSR-mediated immunity. Recent studies have demonstrated that wild-type Rift Valley fever virus efficiently targets and replicates in dendritic cells (DCs). We found that NSR infection of cultured human DCs results in maturation of DCs, characterized by surface upregulation of CD40, CD80, CD86, MHC-I and MHC-II and secretion of the proinflammatory cytokines IFN-β, IL-6 and TNF. Interestingly, expression of the most prominent marker of DC maturation, CD83, was consistently downregulated at 24 hours post infection. Remarkably, NSR infection also completely abrogated CD83 upregulation by LPS. Downregulation of CD83 was not associated with reduced mRNA levels or impaired CD83 mRNA transport from the nucleus and could not be prevented by inhibition of the proteasome or endocytic degradation pathways, suggesting that suppression occurs at the translational level. In contrast to infected cells, bystander DCs displayed full maturation as evidenced by upregulation of CD83. Our results indicate that bystander DCs play an important role in NSR-mediated immunity.
- Published
- 2015
- Full Text
- View/download PDF
7. Preliminary Evaluation of a Bunyavirus Vector for Cancer Immunotherapy.
- Author
-
Oreshkova N, Spel L, Vloet RP, Wichgers Schreur PJ, Moormann RJ, Boes M, and Kortekaas J
- Subjects
- Animals, Cancer Vaccines immunology, Dendritic Cells virology, Epitopes genetics, Epitopes immunology, Humans, Lymphocyte Activation immunology, Lymphoma prevention & control, Lymphoma therapy, Mice, Mice, Inbred C57BL, Phosphoproteins genetics, Phosphoproteins immunology, Rift Valley fever virus genetics, Vaccination, Viral Matrix Proteins genetics, Viral Matrix Proteins immunology, CD8-Positive T-Lymphocytes immunology, Dendritic Cells immunology, Immunotherapy methods, Lymphoma immunology, Rift Valley fever virus immunology
- Abstract
Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8(+) T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
8. Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination.
- Author
-
Wichgers Schreur PJ, Kant J, van Keulen L, Moormann RJ, and Kortekaas J
- Subjects
- Animals, Antibodies, Neutralizing blood, Antibodies, Neutralizing immunology, Antibodies, Viral immunology, Immunity, Active, Injections, Intramuscular, Injections, Subcutaneous, Mutation, Rift Valley fever virus genetics, Sheep, Sheep Diseases virology, Sheep, Domestic virology, Vaccination veterinary, Vaccines, Attenuated, Viremia veterinary, Viremia virology, Antibodies, Viral blood, Rift Valley Fever prevention & control, Rift Valley fever virus immunology, Sheep Diseases prevention & control, Sheep, Domestic immunology, Viral Vaccines immunology
- Abstract
Rift Valley fever virus (RVFV), a mosquito-borne virus in the Bunyaviridae family, causes recurrent outbreaks with severe disease in ruminants and occasionally humans. The virus comprises a segmented genome consisting of a small (S), medium (M) and large (L) RNA segment of negative polarity. The M-segment encodes a glycoprotein precursor (GPC) protein that is co-translationally cleaved into Gn and Gc, which are required for virus entry and fusion. Recently we developed a four-segmented RVFV (RVFV-4s) by splitting the M-genome segment, and used this virus to study RVFV genome packaging. Here we evaluated the potential of a RVFV-4s variant lacking the NSs gene (4s-ΔNSs) to induce protective immunity in sheep. Groups of seven lambs were either mock-vaccinated or vaccinated with 10(5) or 10(6) tissue culture infective dose (TCID50) of 4s-ΔNSs via the intramuscular (IM) or subcutaneous (SC) route. Three weeks post-vaccination all lambs were challenged with wild-type RVFV. Mock-vaccinated lambs developed high fever and high viremia within 2 days post-challenge and three animals eventually succumbed to the infection. In contrast, none of the 4s-ΔNSs vaccinated animals developed clinical signs during the course of the experiment. Vaccination with 10(5) TCID50 via the IM route provided sterile immunity, whereas a 10(6) dose was required to induce sterile immunity via SC vaccination. Protection was strongly correlated with the presence of RVFV neutralizing antibodies. This study shows that 4s-ΔNSs is able to induce sterile immunity in the natural target species after a single vaccination, preferably administrated via the IM route., (Copyright © 2015 Elsevier Ltd. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
9. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
- Author
-
Feenstra F, Maris-Veldhuis M, Daus FJ, Tacken MG, Moormann RJ, van Gennip RG, and van Rijn PA
- Subjects
- Animals, Antibodies, Viral blood, Bluetongue virus genetics, Capsid Proteins genetics, Enzyme-Linked Immunosorbent Assay, Reverse Genetics, Serogroup, Sheep, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated genetics, Vaccines, Attenuated immunology, Vaccines, Marker administration & dosage, Vaccines, Marker immunology, Viral Nonstructural Proteins immunology, Viral Vaccines administration & dosage, Viral Vaccines genetics, Bluetongue virus immunology, Capsid Proteins immunology, Gene Knockout Techniques, Viral Nonstructural Proteins genetics, Viral Vaccines immunology
- Abstract
Bluetongue virus (BTV) causes Bluetongue in ruminants and is transmitted by Culicoides biting midges. Vaccination is the most effective measure to control vector borne diseases; however, there are 26 known BTV serotypes showing little cross protection. The BTV serotype is mainly determined by genome segment 2 encoding the VP2 protein. Currently, inactivated and live-attenuated Bluetongue vaccines are available for a limited number of serotypes, but each of these have their specific disadvantages, including the inability to differentiate infected from vaccinated animals (DIVA). BTV non-structural proteins NS3 and NS3a are not essential for virus replication in vitro, but are important for cytopathogenic effect in mammalian cells and for virus release from insect cells in vitro. Recently, we have shown that virulent BTV8 without NS3/NS3a is non-virulent and viremia in sheep is strongly reduced, whereas local in vivo replication leads to seroconversion. Live-attenuated BTV6 without NS3/NS3a expression protected sheep against BTV challenge. Altogether, NS3/NS3a knockout BTV6 is a promising vaccine candidate and has been named Disabled Infectious Single Animal (DISA) vaccine. Here, we show serotype-specific protection in sheep by DISA vaccine in which only genome segment 2 of serotype 8 was exchanged. Similarly, DISA vaccines against other serotypes could be developed, by exchange of only segment 2, and could therefore safely be combined in multi-serotype cocktail vaccines with respect to reassortment between vaccine viruses. Additionally, NS3 antibody responses are raised after natural BTV infection and NS3-based ELISAs are therefore appropriate tools for DIVA testing accompanying the DISA vaccine. To enable DIVA, we developed an experimental NS3 ELISA. Indeed, vaccinated sheep remained negative for NS3 antibodies, whereas seroconversion for NS3 antibodies was associated with viremia after heterologous BTV challenge., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
10. Serological evidence indicates that foot-and-mouth disease virus serotype O, C and SAT1 are most dominant in eritrea.
- Author
-
Tekleghiorghis T, Moormann RJ, Weerdmeester K, and Dekker A
- Subjects
- Animals, Antibodies, Neutralizing, Cattle, Cattle Diseases blood, Cattle Diseases epidemiology, Cross-Sectional Studies, Enzyme-Linked Immunosorbent Assay methods, Enzyme-Linked Immunosorbent Assay veterinary, Eritrea epidemiology, Foot-and-Mouth Disease blood, Foot-and-Mouth Disease epidemiology, Serogroup, Antibodies, Viral blood, Cattle Diseases virology, Foot-and-Mouth Disease virology, Foot-and-Mouth Disease Virus immunology
- Abstract
Foot-and-mouth disease (FMD) is endemic in Eritrea and in most parts of Africa. To be able to control FMD using vaccination, information on the occurrence of various foot-and-mouth disease serotypes in Eritrea is needed. In this cross-sectional study, 212 sera samples were collected from FMD infected and recovered animals in Eritrea. These samples were tested for the presence of antibodies against FMD non-structural proteins (NSP) and neutralizing antibodies against six of the seven (all but SAT 3) serotypes of FMD virus (FMDV). Of these, 67.0% tested positive to non-structural protein antibodies in the FMD NS ELISA. By virus neutralization, FMDV serotype O antibodies were shown to be the most dominant (approximately 50%). Virus neutralization test results indicate that infection with serotype C and SAT 1 might have occurred, although there are no reports of isolation of these two serotypes. Because the samples were not randomly selected, further random serological surveillance in all age group animals is necessary both to estimate the prevalence of FMD in the country and to confirm the serological results with serotype C and SAT 1., (© 2013 Blackwell Verlag GmbH.)
- Published
- 2014
- Full Text
- View/download PDF
11. No significant differences in the breadth of the foot-and-mouth disease serotype A vaccine induced antibody responses in cattle, using different adjuvants, mixed antigens and different routes of administration.
- Author
-
Tekleghiorghis T, Weerdmeester K, van Hemert-Kluitenberg F, Moormann RJ, and Dekker A
- Subjects
- Animals, Antibodies, Viral blood, Antigens, Viral immunology, Cattle immunology, Cattle Diseases virology, Foot-and-Mouth Disease Virus classification, Serogroup, Vaccination methods, Adjuvants, Immunologic pharmacology, Antibody Formation, Cattle Diseases prevention & control, Foot-and-Mouth Disease prevention & control, Viral Vaccines immunology
- Abstract
Inactivated whole virus foot-and-mouth disease (FMD) vaccines are used worldwide for protection against FMD, but not all vaccines induce protection against all genetic variants of the same FMD virus serotype. The aim of this study is to investigate whether the "breadth" of the antibody response against different strains of the same FMD virus serotype in cattle could be improved by using a different adjuvant, a mix of antigens and/or different routes of administration. To this end, six groups of five cattle were vaccinated with different FMD virus serotype A strain vaccines formulated with Montanide ISA 206 VG adjuvant. Antibody responses for homologous and heterologous cross-reactivity against a panel of 10 different FMD virus serotype A strains were tested by a liquid-phase blocking ELISA. Results of cattle vaccinated with ISA 206 VG adjuvanted vaccine were compared with results obtained in a previous study using aluminium hydroxide-saponin adjuvant. No significant effect of adjuvant on the breadth of the antibody response was observed, neither for mixing of antigens nor for the route of administration (subcutaneous vs. intradermal). Comparison of antigen payload, however, increased both homologous and heterologous titres; a 10-fold higher antigen dose resulted in approximately four times higher titres against all tested strains. Our study shows that breadth of the antibody response depends mainly on the vaccine strain; we therefore propose that, for vaccine preparation, only FMD virus strains are selected that, among other important characteristics, will induce a wide antibody response to different field strains., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
12. Evaluation of nonspreading Rift Valley fever virus as a vaccine vector using influenza virus hemagglutinin as a model antigen.
- Author
-
Oreshkova N, Cornelissen LA, de Haan CA, Moormann RJ, and Kortekaas J
- Subjects
- Administration, Intranasal, Animals, Antibodies, Viral blood, Antigens, Viral immunology, Cytokines immunology, Female, Immunoglobulin G blood, Injections, Intramuscular, Mice, Inbred BALB C, Replicon immunology, Th1 Cells immunology, Vaccination methods, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H1N1 Subtype, Influenza Vaccines immunology, Orthomyxoviridae Infections prevention & control, Rift Valley fever virus immunology
- Abstract
Virus replicon particles are capable of infection, genome replication and gene expression, but are unable to produce progeny virions, rendering their use inherently safe. By virtue of this unique combination of features, replicon particles hold great promise for vaccine applications. We previously developed replicon particles of Rift Valley fever virus (RVFV) and demonstrated their high efficacy as a RVFV vaccine in the natural target species. We have now investigated the feasibility of using this nonspreading RVFV (NSR) as a vaccine vector using influenza virus hemagglutinin as a model antigen. NSR particles were designed to express either the full-length hemagglutinin of influenza A virus H1N1 (NSR-HA) or the respective soluble ectodomain (NSR-sHA). The efficacies of the two NSR vector vaccines, applied via either the intramuscular or the intranasal route, were evaluated. A single vaccination with NSR-HA protected all mice from a lethal challenge dose, while vaccination with NSR-sHA was not protective. Interestingly, whereas intramuscular vaccination elicited superior systemic immune responses, intranasal vaccination provided optimal clinical protection., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
13. Comparative efficacy of two next-generation Rift Valley fever vaccines.
- Author
-
Kortekaas J, Oreshkova N, van Keulen L, Kant J, Bosch BJ, Bouloy M, Moulin V, Goovaerts D, and Moormann RJ
- Subjects
- Animals, Antibodies, Viral blood, Neutralization Tests, RNA, Viral blood, Random Allocation, Reassortant Viruses immunology, Rift Valley fever virus immunology, Sheep immunology, Sheep Diseases virology, Vaccines, Attenuated immunology, Viremia, Rift Valley Fever prevention & control, Sheep Diseases prevention & control, Viral Vaccines immunology
- Abstract
Rift Valley fever virus (RVFV) is a re-emerging zoonotic bunyavirus of the genus Phlebovirus. A natural isolate containing a large attenuating deletion in the small (S) genome segment previously yielded a highly effective vaccine virus, named Clone 13. The deletion in the S segment abrogates expression of the NSs protein, which is the major virulence factor of the virus. To develop a vaccine of even higher safety, a virus named R566 was created by natural laboratory reassortment. The R566 virus combines the S segment of the Clone 13 virus with additional attenuating mutations on the other two genome segments M and L, derived from the previously created MP-12 vaccine virus. To achieve the same objective, a nonspreading RVFV (NSR-Gn) was created by reverse-genetics, which not only lacks the NSs gene but also the complete M genome segment. We have now compared the vaccine efficacies of these two next-generation vaccines and included the Clone 13 vaccine as a control for optimal efficacy. Groups of eight lambs were vaccinated once and challenged three weeks later. All mock-vaccinated lambs developed high fever and viremia and three lambs did not survive the infection. As expected, lambs vaccinated with Clone 13 were protected from viremia and clinical signs. Two lambs vaccinated with R566 developed mild fever after challenge infection, which was associated with low levels of viral RNA in the blood, whereas vaccination with the NSR-Gn vaccine completely prevented viremia and clinical signs., (Copyright © 2014 Elsevier Ltd. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
14. Creation of Rift Valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging.
- Author
-
Wichgers Schreur PJ, Oreshkova N, Moormann RJ, and Kortekaas J
- Subjects
- Animals, Culicidae virology, Female, Humans, Mice, Mice, Inbred BALB C, RNA, Viral genetics, Rift Valley fever virus physiology, Virion genetics, Genome, Viral, Rift Valley Fever virology, Rift Valley fever virus genetics, Virion physiology, Virus Assembly
- Abstract
Unlabelled: Bunyavirus genomes comprise a small (S), a medium (M), and a large (L) RNA segment of negative polarity. Although the untranslated regions have been shown to comprise signals required for transcription, replication, and encapsidation, the mechanisms that drive the packaging of at least one S, M, and L segment into a single virion to generate infectious virus are largely unknown. One of the most important members of the Bunyaviridae family that causes devastating disease in ruminants and occasionally humans is the Rift Valley fever virus (RVFV). We studied the flexibility of RVFV genome packaging by splitting the glycoprotein precursor gene, encoding the (NSm)GnGc polyprotein, into two individual genes encoding either (NSm)Gn or Gc. Using reverse genetics, six viruses with a segmented glycoprotein precursor gene were rescued, varying from a virus comprising two S-type segments in the absence of an M-type segment to a virus consisting of four segments (RVFV-4s), of which three are M-type. Despite that all virus variants were able to grow in mammalian cell lines, they were unable to spread efficiently in cells of mosquito origin. Moreover, in vivo studies demonstrated that RVFV-4s is unable to cause disseminated infection and disease in mice, even in the presence of the main virulence factor NSs, but induced a protective immune response against a lethal challenge with wild-type virus. In summary, splitting bunyavirus glycoprotein precursor genes provides new opportunities to study bunyavirus genome packaging and offers new methods to develop next-generation live-attenuated bunyavirus vaccines., Importance: Rift Valley fever virus (RVFV) causes devastating disease in ruminants and occasionally humans. Virions capable of productive infection comprise at least one copy of the small (S), medium (M), and large (L) RNA genome segments. The M segment encodes a glycoprotein precursor (GPC) protein that is cotranslationally cleaved into Gn and Gc, which are required for virus entry and fusion. We studied the flexibility of RVFV genome packaging and developed experimental live-attenuated vaccines by applying a unique strategy based on the splitting of the GnGc open reading frame. Several RVFV variants, varying from viruses comprising two S-type segments to viruses consisting of four segments (RVFV-4s), of which three are M-type, could be rescued and were shown to induce a rapid protective immune response. Altogether, the segmentation of bunyavirus GPCs provides a new method for studying bunyavirus genome packaging and facilitates the development of novel live-attenuated bunyavirus vaccines., (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)
- Published
- 2014
- Full Text
- View/download PDF
15. Comparison of test methodologies for foot-and-mouth disease virus serotype A vaccine matching.
- Author
-
Tekleghiorghis T, Weerdmeester K, van Hemert-Kluitenberg F, Moormann RJ, and Dekker A
- Subjects
- Animals, Antibodies, Neutralizing blood, Antibodies, Viral blood, Cattle, Enzyme-Linked Immunosorbent Assay methods, Neutralization Tests methods, Sensitivity and Specificity, Viral Vaccines administration & dosage, Foot-and-Mouth Disease Virus immunology, Viral Vaccines immunology
- Abstract
Vaccination has been one of the most important interventions in disease prevention and control. The impact of vaccination largely depends on the quality and suitability of the chosen vaccine. To determine the suitability of a vaccine strain, antigenic matching is usually studied by in vitro analysis. In this study, we performed three in vitro test methods to determine which one gives the lowest variability and the highest discriminatory capacity. Binary ethylenimine inactivated vaccines, prepared from 10 different foot-and-mouth disease (FMD) virus serotype A strains, were used to vaccinate cattle (5 animals for each strain). The antibody titers in blood serum samples 3 weeks postvaccination (w.p.v.) were determined by a virus neutralization test, neutralization index test, and liquid-phase blocking enzyme-linked immunosorbent assay (ELISA). The titers were then used to calculate relationship coefficient (r1) values. These r1 values were compared to the genetic lineage using receiver operating characteristic (ROC) analysis. In the two neutralization test methods, the median titers observed against the test strains differed considerably, and the sera of the vaccinated animals did not always show the highest titers against their respective homologous virus strains. When the titers were corrected for test strain effect (scaling), the variability (standard error of the mean per vaccinated group) increased because the results were on a different scale, but the discriminatory capacity improved. An ROC analysis of the r1 value calculated on both observed and scaled titers showed that only r1 values of the liquid-phase blocking ELISA gave a consistent statistically significant result. Under the conditions of the present study, the liquid-phase blocking ELISA showed less variation and still had a higher discriminatory capacity than the other tests.
- Published
- 2014
- Full Text
- View/download PDF
16. Transplacental transmission of Bluetongue virus serotype 1 and serotype 8 in sheep: virological and pathological findings.
- Author
-
van der Sluijs MT, Schroer-Joosten DP, Fid-Fourkour A, Vrijenhoek MP, Debyser I, Moulin V, Moormann RJ, and de Smit AJ
- Subjects
- Animals, Female, Incidence, Pregnancy, Pregnancy Complications, Infectious virology, Serotyping, Sheep, Sheep, Domestic, Bluetongue transmission, Bluetongue virus classification, Infectious Disease Transmission, Vertical, Pregnancy Complications, Infectious epidemiology
- Abstract
The Bluetongue virus serotype 8 (BTV-8) strain, which emerged in Europe in 2006, had an unusually high ability to cause foetal infection in pregnant ruminants. Other serotypes of BTV had already been present in Europe for more than a decade, but transplacental transmission of these strains had never been demonstrated. To determine whether transplacental transmission is a unique feature of BTV-8 we compared the incidence and pathological consequences of transplacental transmission of BTV-8 to that of BTV-1. Nine pregnant ewes were infected with either BTV-8 or BTV-1. The BTV strains used for the infection were field strains isolated on embryonated chicken eggs and passaged twice on mammalian cells. Blood samples were taken to monitor the viraemia in the ewes. Four weeks after the infection, the foetuses were examined for pathological changes and for the presence of BTV. BTV-8 could be demonstrated in 12 foetuses (43%) from 5 ewes (56%). %). BTV-1 was detected in 14 foetuses (82%) from 6 ewes (67%). Pathological changes were mainly found in the central nervous system. In the BTV-8 group, lympho-histiocytic infiltrates, gliosis and slight vacuolation of the neuropil were found. BTV-1 infection induced a severe necrotizing encephalopathy and severe meningitis, with macroscopic hydranencephaly or porencephaly in 8 foetuses. In our experimental setting, using low passaged virus strains, BTV-1 was able to induce transplacental transmission to a higher incidence compared to BTV-8, causing more severe pathology.
- Published
- 2013
- Full Text
- View/download PDF
17. A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs.
- Author
-
Oreshkova N, van Keulen L, Kant J, Moormann RJ, and Kortekaas J
- Subjects
- Animals, Cell Line, Cricetinae, Female, Genome, Viral, Humans, Mice, Mice, Inbred BALB C, Pregnancy, Sheep, Viral Vaccines immunology, CD4-Positive T-Lymphocytes immunology, Immunity, Cellular, Immunologic Memory, Rift Valley Fever immunology, Rift Valley Fever prevention & control, Rift Valley fever virus immunology, Vaccination, Viral Vaccines pharmacology
- Abstract
Rift Valley fever virus (RVFV) is an important pathogen that affects ruminants and humans. Recently we developed a vaccine based on nonspreading RVFV (NSR) and showed that a single vaccination with this vaccine protects lambs from viremia and clinical signs. However, low levels of viral RNA were detected in the blood of vaccinated lambs shortly after challenge infection. These low levels of virus, when present in a pregnant ewe, could potentially infect the highly susceptible fetus. We therefore aimed to further improve the efficacy of the NSR vaccine. Here we report the expression of Gn, the major immunogenic protein of the virus, from the NSR genome. The resulting NSR-Gn vaccine was shown to elicit superior CD8 and CD4-restricted memory responses and improved virus neutralization titers in mice. A dose titration study in lambs revealed that the highest vaccination dose of 10(6.3) TCID50/ml protected all lambs from clinical signs and viremia. The lambs developed neutralizing antibodies within three weeks after vaccination and no anamnestic responses were observed following challenge. The combined results suggest that sterile immunity was achieved by a single vaccination with the NSR-Gn vaccine.
- Published
- 2013
- Full Text
- View/download PDF
18. Transplacental transmission of BTV-8 in sheep: BTV viraemia, antibody responses and vaccine efficacy in lambs infected in utero.
- Author
-
van der Sluijs MT, Schroer-Joosten DP, Fid-Fourkour A, Smit M, Vrijenhoek MP, Moulin V, de Smit AJ, and Moormann RJ
- Subjects
- Animals, Antibodies, Neutralizing blood, Antibodies, Viral blood, Bluetongue immunology, Bluetongue virus, Female, Pregnancy, Pregnancy Complications, Infectious veterinary, Pregnancy Complications, Infectious virology, Sheep, Domestic virology, Vaccination veterinary, Vaccines, Inactivated immunology, Vaccines, Inactivated therapeutic use, Viral Load, Viral Vaccines therapeutic use, Bluetongue transmission, Infectious Disease Transmission, Vertical veterinary, Sheep, Domestic immunology, Viral Vaccines immunology, Viremia immunology
- Abstract
Bluetongue virus (BTV) is an insect vector transmitted virus which causes an economically important disease in ruminants. BTV infection during pregnancy can result in infection of the foetus, which may lead to the birth of persistently infected or immunotolerant offspring. Since persistently infected animals continuously produce large amounts of virus they could be a source of infection for the insect vector. This could significantly influence the epidemiology of the virus and hence might require additional measures to control a BTV outbreak. Therefore, we investigated the potential of BTV-8 to induce persistent infection or immunotolerance in lambs in an experimental setting. Infection of eighteen 70-75 days pregnant ewes with wild type BTV-8 led to the birth of 25 out of 44 BTV RNA positive lambs (foetal infected, FI). All 23 FI lambs born alive also had anti BTV antibodies at birth; infectious virus could be recovered from 5 out of 25 FI lambs. Viral RNA loads decreased rapidly after birth; 19 out of 20 FI lambs that remained in the experiment until week 14 after birth, were RNA negative at that time. Since persistence of BTV-8 infection could not be demonstrated, we investigated whether foetal infection had an effect on protection against a field virus infection and on efficacy of vaccination. To this end, 5 FI lambs and 5 foetal non-infected (FNI) lambs were vaccinated with the inactivated Bovilis(®) BTV-8 vaccine, five months after birth. Three weeks after the vaccination, all lambs were infected with wild type BTV-8. The foetal infection did not interfere with vaccination efficacy. In contrast, foetal BTV-8 infection induced an immune response which afforded protection against BTV challenge comparable to the level of protection induced by vaccination., (Copyright © 2013 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
19. Vertical transmission of Rift Valley fever virus without detectable maternal viremia.
- Author
-
Antonis AF, Kortekaas J, Kant J, Vloet RP, Vogel-Brink A, Stockhofe N, and Moormann RJ
- Subjects
- Animals, Antibodies, Viral blood, Female, Netherlands epidemiology, Pregnancy, Pregnancy Complications, Infectious mortality, Pregnancy Complications, Infectious virology, RNA, Viral analysis, Real-Time Polymerase Chain Reaction veterinary, Rift Valley Fever mortality, Rift Valley Fever virology, Rift Valley fever virus isolation & purification, Sheep, Sheep Diseases mortality, Sheep Diseases virology, Viremia veterinary, Infectious Disease Transmission, Vertical veterinary, Pregnancy Complications, Infectious veterinary, Rift Valley Fever transmission, Rift Valley fever virus physiology, Sheep Diseases transmission
- Abstract
Rift Valley fever virus (RVFV) is a zoonotic bunyavirus that causes abortions in domesticated ruminants. Sheep breeds exotic to endemic areas are reportedly the most susceptible to RVFV infection. Within the scope of a risk assessment program of The Netherlands, we investigated the susceptibility of a native breed of gestating sheep to RVFV infection. Ewes were infected experimentally during the first, second, or third trimester of gestation. Mortality was high among ewes that developed viremia. Four of 11 inoculated ewes, however, did not develop detectable viremia nor clinical signs and did not seroconvert for immunoglobulin G (IgG) or IgM antibodies. Surprisingly, these ewes were found to contain viral RNA in maternal and fetal organs, and the presence of live virus in fetal organs was demonstrated by virus isolation. We demonstrate that RVFV can be transmitted vertically in the absence of detectable maternal viremia.
- Published
- 2013
- Full Text
- View/download PDF
20. Effect of natural and chimeric haemagglutinin genes on influenza A virus replication in baby hamster kidney cells.
- Author
-
van Wielink R, Harmsen MM, Martens DE, de Leeuw OS, Peeters BP, Wijffels RH, and Moormann RJ
- Subjects
- Animals, Biotechnology, Cell Line, Cricetinae, Hemagglutinins metabolism, Influenza A Virus, H1N1 Subtype genetics, Influenza A Virus, H1N1 Subtype metabolism, Influenza Vaccines biosynthesis, Influenza Vaccines genetics, Kidney cytology, Recombinant Fusion Proteins metabolism, Virus Replication genetics, Hemagglutinins genetics, Influenza A Virus, H1N1 Subtype physiology, Recombinant Fusion Proteins genetics, Virus Replication physiology
- Abstract
Baby hamster kidney (BHK21) cells are used to produce vaccines against various viral veterinary diseases, including rabies and foot-and-mouth-disease. Although particular influenza virus strains replicate efficiently in BHK21 cells the general use of these cells for influenza vaccine production is prohibited by the poor replication of most strains, including model strain A/PR/8/34 [H1N1] (PR8). We now show that in contrast to PR8, the related strain A/WSN/33 [H1N1] (WSN) replicates efficiently in BHK21 cells. This difference is determined by the haemagglutinin (HA) protein since reciprocal reassortant viruses with swapped HAs behave similarly with respect to growth on BHK21 cells as the parental virus from which their HA gene is derived. The ability or inability of six other influenza virus strains to grow on BHK21 cells appears to be similarly dependent on the nature of the HA gene since reassortant PR8 viruses containing the HA of these strains grow to similar titres as the parental virus from which the HA gene was derived. However, the growth to low titres of a seventh influenza strain was not due to the nature of the HA gene since a reassortant PR8 virus containing this HA grew efficiently on BHK21 cells. Taken together, these results suggest that the HA gene often primarily determines influenza replication efficiency on BHK21 cells but that in some strains other genes are also involved. High virus titres could be obtained with reassortant PR8 strains that contained a chimeric HA consisting of the HA1 domain of PR8 and the HA2 domain of WSN. HA1 contains most antigenic sites and is therefore important for vaccine efficacy. This method of producing the HA1 domain as fusion to a heterologous HA2 domain could possibly also be used for the production of HA1 domains of other viruses to enable the use of BHK21 cells as a generic platform for veterinary influenza vaccine production., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
21. Heparan sulfate facilitates Rift Valley fever virus entry into the cell.
- Author
-
de Boer SM, Kortekaas J, de Haan CA, Rottier PJ, Moormann RJ, and Bosch BJ
- Subjects
- Animals, CHO Cells, Cricetinae, Cricetulus, Viral Tropism, Heparitin Sulfate physiology, Membrane Fusion physiology, Rift Valley fever virus physiology
- Abstract
Rift Valley fever virus (RVFV), an emerging arthropod-borne pathogen, has a broad host and cell tropism. Here we report that the glycosaminoglycan heparan sulfate, abundantly present on the surface of most animal cells, is required for efficient entry of RVFV. Entry was significantly reduced by preincubating the virus inoculum with highly sulfated heparin, by enzymatic removal of heparan sulfate from cells and in cells genetically deficient in heparan sulfate synthesis.
- Published
- 2012
- Full Text
- View/download PDF
22. Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein.
- Author
-
de Boer SM, Kortekaas J, Spel L, Rottier PJ, Moormann RJ, and Bosch BJ
- Subjects
- Animals, Base Sequence, Blotting, Western, Cell Line, Cricetinae, DNA Primers, Drosophila, Electrophoresis, Polyacrylamide Gel, Endocytosis, Flow Cytometry, Hydrogen-Ion Concentration, Microscopy, Fluorescence, Protein Conformation, Viral Fusion Proteins chemistry, Acids metabolism, Rift Valley fever virus metabolism, Viral Fusion Proteins metabolism
- Abstract
The entry of the enveloped Rift Valley fever virus (RVFV) into its host cell is mediated by the viral glycoproteins Gn and Gc. We investigated the RVFV entry process and, in particular, its pH-dependent activation mechanism using our recently developed nonspreading-RVFV-particle system. Entry of the virus into the host cell was efficiently inhibited by lysosomotropic agents that prevent endosomal acidification and by compounds that interfere with dynamin- and clathrin-dependent endocytosis. Exposure of plasma membrane-bound virions to an acidic pH (
- Published
- 2012
- Full Text
- View/download PDF
23. Mutations in the M-gene segment can substantially increase replication efficiency of NS1 deletion influenza A virus in MDCK cells.
- Author
-
van Wielink R, Harmsen MM, Martens DE, Peeters BP, Wijffels RH, and Moormann RJ
- Subjects
- Animals, Apoptosis, Base Sequence, Chlorocebus aethiops, Dogs, Genome, Viral, Humans, Influenza Vaccines metabolism, Madin Darby Canine Kidney Cells, Molecular Sequence Data, Mutation, Sequence Analysis, DNA, Vero Cells, Viral Nonstructural Proteins chemistry, Viral Nonstructural Proteins genetics, Virus Replication, Influenza A virus genetics, Viral Nonstructural Proteins metabolism
- Abstract
Influenza viruses unable to express NS1 protein (delNS1) replicate poorly and induce large amounts of interferon (IFN). They are therefore considered candidate viruses for live-attenuated influenza vaccines. Their attenuated replication is generally assumed to result from the inability to counter the antiviral host response, as delNS1 viruses replicate efficiently in Vero cells, which lack IFN expression. In this study, delNS1 virus was parallel passaged on IFN-competent MDCK cells, which resulted in two strains that were able to replicate to high virus titers in MDCK cells due to adaptive mutations especially in the M-gene segment but also in the NP and NS gene segments. Most notable were clustered U-to-C mutations in the M segment of both strains and clustered A-to-G mutations in the NS segment of one strain, which presumably resulted from host cell-mediated RNA editing. The M segment mutations in both strains changed the ratio of M1 to M2 expression, probably by affecting splicing efficiency. In one virus, 2 amino acid substitutions in M1 additionally enhanced virus replication, possibly through changes in the M1 distribution between the nucleus and the cytoplasm. Both adapted viruses induced levels of IFN equal to that of the original delNS1 virus. These results show that the increased replication of the adapted viruses is not primarily due to altered IFN induction but rather is related to changes in M1 expression or localization. The mutations identified in this paper may be used to enhance delNS1 virus replication for vaccine production.
- Published
- 2012
- Full Text
- View/download PDF
24. Efficacy of three candidate Rift Valley fever vaccines in sheep.
- Author
-
Kortekaas J, Antonis AF, Kant J, Vloet RP, Vogel A, Oreshkova N, de Boer SM, Bosch BJ, and Moormann RJ
- Subjects
- Adjuvants, Immunologic administration & dosage, Animals, Antibodies, Neutralizing blood, Antibodies, Viral blood, Disease Models, Animal, Fever prevention & control, Rift Valley Fever immunology, Sheep, Survival Analysis, Vaccines, Attenuated administration & dosage, Vaccines, Attenuated immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Viremia prevention & control, Rift Valley Fever prevention & control, Rift Valley fever virus immunology, Viral Vaccines administration & dosage, Viral Vaccines immunology
- Abstract
Rift Valley fever virus (RVFV) is a mosquito-transmitted Bunyavirus that causes high morbidity and mortality among ruminants and humans. The virus is endemic to the African continent and the Arabian Peninsula and continues to spread into new areas. The explosive nature of RVF outbreaks requires that vaccines provide swift protection after a single vaccination. We recently developed several candidate vaccines and here report their efficacy in lambs within three weeks after a single vaccination. The first vaccine comprises the purified ectodomain of the Gn structural glycoprotein formulated in a water-in-oil adjuvant. The second vaccine is based on a Newcastle disease virus-based vector that produces both RVFV structural glycoproteins Gn and Gc. The third vaccine comprises a recently developed nonspreading RVFV. The latter two vaccines were administered without adjuvant. The inactivated whole virus-based vaccine produced by Onderstepoort Biological Products was used as a positive control. Five out of six mock-vaccinated lambs developed high viremia and fever and one lamb succumbed to the challenge infection. A single vaccination with each vaccine resulted in a neutralizing antibody response within three weeks after vaccination and protected lambs from viremia, pyrexia and mortality., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
25. Effect of vaccination with an inactivated vaccine on transplacental transmission of BTV-8 in mid term pregnant ewes and heifers.
- Author
-
van der Sluijs MT, Schroer-Joosten DP, Fid-Fourkour A, Vrijenhoek MP, Debyser I, Gregg DA, Dufe DM, Moulin V, Moormann RJ, and de Smit AJ
- Subjects
- Aborted Fetus pathology, Animals, Bluetongue pathology, Bluetongue transmission, Bluetongue virus pathogenicity, Cattle, Female, Placenta pathology, Pregnancy, Pregnancy Complications, Infectious pathology, Sheep, Vaccines, Inactivated administration & dosage, Vaccines, Inactivated immunology, Viral Vaccines administration & dosage, Bluetongue prevention & control, Bluetongue virus immunology, Infectious Disease Transmission, Vertical prevention & control, Pregnancy Complications, Infectious prevention & control, Viral Vaccines immunology
- Abstract
The effect of vaccination with a commercial inactivated Bluetongue virus serotype 8 (BTV-8) vaccine on the ability of BTV-8 to cross the ruminant placenta was investigated in two experiments. Ten pregnant ewes (Experiment 1) or heifers (Experiment 2) were vaccinated according to the manufacturer's instructions. Three weeks after the completion of the vaccination schedule, all vaccinated animals were infected with BTV-8 together with ten non-vaccinated pregnant animals that served as challenged controls. Four additional pregnant animals received a mock challenge at the same time point. Three weeks after the challenge, the foetuses were collected. In the sheep experiment, the lambs of the vaccinated ewes and the mock infected ewes were negative in the virus isolation, whereas BTV-8 could be isolated from 11/23 lambs of 6/10 ewes in the BTV-8 challenged control group. The incidence and severity of BTV associated lesions, such as haemorrhages, meningitis/encephalitis and necrosis in the placentomes was significantly higher in the BTV-8 challenged control group. The rate of transplacental transmission was less in the cattle experiment: BTV-8 could be detected in 2/10 calves in the BTV-8 challenged control group. All other calves were negative. Vaccination clearly reduced transplacental transmission of BTV-8 in the sheep experiment, whereas in the cattle experiment, the incidence of transmission was too low to demonstrate a significant reduction of transmission by vaccination. However, the vaccine very effectively blocked viraemia, which suggests that the vaccine might prevent transmission in cattle as well. Transplacental transmission of BTV has serious economical consequences, due to the loss of progeny to the livestock industry. Vaccination can be an important aid in the reduction of these economic losses., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
26. Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice.
- Author
-
Cornelissen LA, de Leeuw OS, Tacken MG, Klos HC, de Vries RP, de Boer-Luijtze EA, van Zoelen-Bos DJ, Rigter A, Rottier PJ, Moormann RJ, and de Haan CA
- Subjects
- Animals, Antibody Formation immunology, Chickens immunology, Chickens virology, Female, Hemagglutinin Glycoproteins, Influenza Virus chemistry, Hemagglutinin Glycoproteins, Influenza Virus isolation & purification, Humans, Influenza in Birds blood, Influenza in Birds virology, Mice, Mice, Inbred BALB C, Orthomyxoviridae Infections virology, Protein Multimerization, Recombination, Genetic genetics, Solubility, Treatment Outcome, Vaccination, Virus Shedding immunology, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H5N1 Subtype immunology, Influenza in Birds immunology, Influenza in Birds prevention & control, Newcastle disease virus immunology, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control
- Abstract
Background: Highly pathogenic avian influenza virus (HPAIV) causes a highly contagious often fatal disease in poultry, resulting in significant economic losses in the poultry industry. HPAIV H5N1 also poses a major public health threat as it can be transmitted directly from infected poultry to humans. One effective way to combat avian influenza with pandemic potential is through the vaccination of poultry. Several live vaccines based on attenuated Newcastle disease virus (NDV) that express influenza hemagglutinin (HA) have been developed to protect chickens or mammalian species against HPAIV. However, the zoonotic potential of NDV raises safety concerns regarding the use of live NDV recombinants, as the incorporation of a heterologous attachment protein may result in the generation of NDV with altered tropism and/or pathogenicity., Methodology/principal Findings: In the present study we generated recombinant NDVs expressing either full length, membrane-anchored HA of the H5 subtype (NDV-H5) or a soluble trimeric form thereof (NDV-sH5(3)). A single intramuscular immunization with NDV-sH5(3) or NDV-H5 fully protected chickens against disease after a lethal challenge with H5N1 and reduced levels of virus shedding in tracheal and cloacal swabs. NDV-sH5(3) was less protective than NDV-H5 (50% vs 80% protection) when administered via the respiratory tract. The NDV-sH5(3) was ineffective in mice, regardless of whether administered oculonasally or intramuscularly. In this species, NDV-H5 induced protective immunity against HPAIV H5N1, but only after oculonasal administration, despite the poor H5-specific serum antibody response it elicited., Conclusions/significance: Although NDV expressing membrane anchored H5 in general provided better protection than its counterpart expressing soluble H5, chickens could be fully protected against a lethal challenge with H5N1 by using the latter NDV vector. This study thus provides proof of concept for the use of recombinant vector vaccines expressing a soluble form of a heterologous viral membrane protein. Such vectors may be advantageous as they preclude the incorporation of heterologous membrane proteins into the viral vector particles.
- Published
- 2012
- Full Text
- View/download PDF
27. Creation of a nonspreading Rift Valley fever virus.
- Author
-
Kortekaas J, Oreshkova N, Cobos-Jiménez V, Vloet RP, Potgieter CA, and Moormann RJ
- Subjects
- Animals, Blotting, Northern, Cricetinae, Enzyme-Linked Immunosorbent Assay, Female, Genetic Engineering, Green Fluorescent Proteins genetics, Injections, Intramuscular, Kidney cytology, Kidney metabolism, Kidney virology, Mice, Mice, Inbred BALB C, Plasmids, Recombination, Genetic, Rift Valley Fever genetics, Survival Rate, Vaccination, Viral Nonstructural Proteins metabolism, Virus Internalization, Genome, Viral, Green Fluorescent Proteins metabolism, Replicon genetics, Rift Valley Fever virology, Rift Valley fever virus pathogenicity, Virus Replication
- Abstract
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic bunyavirus of the genus Phlebovirus and a serious human and veterinary pathogen. RVFV contains a three-segmented RNA genome, which is comprised of the large (L), medium (M), and small (S) segments. The proteins that are essential for genome replication are encoded by the L and S segments, whereas the structural glycoproteins are encoded by the M segment. We have produced BHK replicon cell lines (BHK-Rep) that maintain replicating L and S genome segments. Transfection of BHK-Rep cells with a plasmid encoding the structural glycoproteins results in the efficient production of RVFV replicon particles (RRPs). To facilitate monitoring of infection, the NSs gene was replaced with an enhanced green fluorescent protein gene. RRPs are infectious for both mammalian and insect cells but are incapable of autonomous spreading, rendering their application outside biosafety containment completely safe. We demonstrate that a single intramuscular vaccination with RRPs protects mice from a lethal dose of RVFV and show that RRPs can be used for rapid virus neutralization tests that do not require biocontainment facilities. The methods reported here will greatly facilitate vaccine and drug development as well as fundamental studies on RVFV biology. Moreover, it may be possible to develop similar systems for other members of the bunyavirus family as well.
- Published
- 2011
- Full Text
- View/download PDF
28. Efficacy of a pandemic (H1N1) 2009 virus vaccine in pigs against the pandemic influenza virus is superior to commercially available swine influenza vaccines.
- Author
-
Loeffen WL, Stockhofe N, Weesendorp E, van Zoelen-Bos D, Heutink R, Quak S, Goovaerts D, Heldens JG, Maas R, Moormann RJ, and Koch G
- Subjects
- Animals, Influenza A Virus, H1N1 Subtype isolation & purification, Influenza A Virus, H3N2 Subtype genetics, Influenza A Virus, H3N2 Subtype immunology, Orthomyxoviridae Infections immunology, Orthomyxoviridae Infections prevention & control, Reassortant Viruses immunology, Sus scrofa, Swine, Swine Diseases virology, Vaccines, Inactivated immunology, Influenza A Virus, H1N1 Subtype physiology, Influenza Vaccines immunology, Orthomyxoviridae Infections veterinary, Swine Diseases immunology, Swine Diseases prevention & control
- Abstract
In April 2009 a new influenza A/H1N1 strain, currently named "pandemic (H1N1) influenza 2009" (H1N1v), started the first official pandemic in humans since 1968. Several incursions of this virus in pig herds have also been reported from all over the world. Vaccination of pigs may be an option to reduce exposure of human contacts with infected pigs, thereby preventing cross-species transfer, but also to protect pigs themselves, should this virus cause damage in the pig population. Three swine influenza vaccines, two of them commercially available and one experimental, were therefore tested and compared for their efficacy against an H1N1v challenge. One of the commercial vaccines is based on an American classical H1N1 influenza strain, the other is based on a European avian H1N1 influenza strain. The experimental vaccine is based on reassortant virus NYMC X179A (containing the hemagglutinin (HA) and neuraminidase (NA) genes of A/California/7/2009 (H1N1v) and the internal genes of A/Puerto Rico/8/34 (H1N1)). Excretion of infectious virus was reduced by 0.5-3 log(10) by the commercial vaccines, depending on vaccine and sample type. Both vaccines were able to reduce virus replication especially in the lower respiratory tract, with less pathological lesions in vaccinated and subsequently challenged pigs than in unvaccinated controls. In pigs vaccinated with the experimental vaccine, excretion levels of infectious virus in nasal and oropharyngeal swabs, were at or below 1 log(10)TCID(50) per swab and lasted for only 1 or 2 days. An inactivated vaccine containing the HA and NA of an H1N1v is able to protect pigs from an infection with H1N1v, whereas swine influenza vaccines that are currently available are of limited efficaciousness. Whether vaccination of pigs against H1N1v will become opportune remains to be seen and will depend on future evolution of this strain in the pig population. Close monitoring of the pig population, focussing on presence and evolution of influenza strains on a cross-border level would therefore be advisable., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
29. MDCK cell line with inducible allele B NS1 expression propagates delNS1 influenza virus to high titres.
- Author
-
van Wielink R, Harmsen MM, Martens DE, Peeters BP, Wijffels RH, and Moormann RJ
- Subjects
- Animals, Apoptosis genetics, Cell Line, Chlorocebus aethiops, Dogs, Influenza A Virus, H1N1 Subtype genetics, Influenza A Virus, H1N1 Subtype immunology, Influenza A Virus, H1N1 Subtype metabolism, Influenza A Virus, H5N1 Subtype genetics, Influenza A Virus, H5N1 Subtype immunology, Influenza A Virus, H5N1 Subtype metabolism, Influenza A virus immunology, Influenza Vaccines genetics, Influenza Vaccines metabolism, Interferon-beta genetics, Interferon-beta metabolism, Recombinant Proteins biosynthesis, Recombinant Proteins genetics, Recombinant Proteins immunology, Vaccines, Attenuated genetics, Vaccines, Attenuated metabolism, Vero Cells, Viral Load, Viral Nonstructural Proteins immunology, Alleles, Influenza A virus genetics, Influenza A virus metabolism, Viral Nonstructural Proteins biosynthesis, Viral Nonstructural Proteins genetics, Virus Replication genetics
- Abstract
Influenza A viruses lacking the gene encoding the non-structural NS1 protein (delNS1) have potential use as live attenuated vaccines. However, due to the lack of NS1, virus replication in cell culture is considerably reduced, prohibiting commercial vaccine production. We therefore established two stable MDCK cell lines that show inducible expression of the allele B NS1 protein. Upon induction, both cell lines expressed NS1 to about 1000-fold lower levels than influenza virus-infected cells. Nevertheless, expression of NS1 increased delNS1 virus titres to levels comparable to those obtained with an isogenic virus strain containing an intact NS1 gene. Recombinant NS1 expression increased the infectious virus titres 244 to 544-fold and inhibited virus induced apoptosis. However, NS1 expression resulted in only slightly, statistically not significant, reduced levels of interferon-β production. Thus, the low amount of recombinant NS1 is sufficient to restore delNS1 virus replication in MDCK cells, but it remains unclear whether this occurs in an interferon dependent manner. In contrast to previous findings, recombinant NS1 expression did not induce apoptosis, nor did it affect cell growth. These cell lines thus show potential to improve the yield of delNS1 virus for vaccine production., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
30. Rift Valley Fever Vaccine Development, Progress and Constraints.
- Author
-
Kortekaas J, Zingeser J, de Leeuw P, de La Rocque S, Unger H, and Moormann RJ
- Subjects
- Animals, Consensus Development Conferences as Topic, Humans, Rift Valley Fever prevention & control, Vaccines, Attenuated, Rift Valley Fever veterinary, Rift Valley fever virus immunology, Viral Vaccines
- Published
- 2011
- Full Text
- View/download PDF
31. Vaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virus.
- Author
-
Loeffen WL, de Vries RP, Stockhofe N, van Zoelen-Bos D, Maas R, Koch G, Moormann RJ, Rottier PJ, and de Haan CA
- Subjects
- Animals, Antibodies, Viral blood, Hemagglutination Inhibition Tests, Neutralization Tests, Orthomyxoviridae Infections immunology, Recombinant Proteins immunology, Swine, Vaccines, Synthetic immunology, Virus Shedding, Hemagglutinin Glycoproteins, Influenza Virus immunology, Influenza A Virus, H1N1 Subtype immunology, Influenza Vaccines immunology, Orthomyxoviridae Infections prevention & control
- Abstract
In 2009 a new influenza A/H1N1 virus strain ("pandemic (H1N1) 2009", H1N1v) emerged that rapidly spread around the world. The virus is suspected to have originated in swine through reassortment and to have subsequently crossed the species-barrier towards humans. Several cases of reintroduction into pigs have since been reported, which could possibly create a reservoir for human exposure or ultimately become endemic in the pig population with similar clinical disease problems as current swine influenza strains. A soluble trimer of hemagglutinin (HA), derived from the H1N1v, was used as a vaccine in pigs to investigate the extent to which this vaccine would be able to protect pigs against infection with the H1N1v influenza strain, especially with respect to reducing virus replication and excretion. In a group of unvaccinated control pigs, no clinical symptoms were observed, but (histo)pathological changes consistent with an influenza infection were found on days 1 and 3 after inoculation. Live virus was isolated from the upper and lower respiratory tract, with titres up to 10(6) TCID(50) per gram of tissue. Furthermore, live virus was detected in brain samples. Control pigs were shedding live virus for up to 6 days after infection, with titres of up to 10(5) TCID(50) per nasal or oropharyngeal swab. The soluble H1N1v HA trimer diminished virus replication and excretion after a double vaccination and subsequent challenge. Live virus could not be detected in any of the samples taken from the vaccinated pigs. Vaccines based on soluble HA trimers provide an attractive alternative to the current inactivated vaccines., (Copyright © 2011 Elsevier Ltd. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
32. Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety.
- Author
-
Harmsen MM, Antonis AF, Moormann RJ, and Kortekaas J
- Subjects
- Animals, Cattle, Immunity, Humoral genetics, Immunity, Humoral immunology, Mice, Rift Valley fever virus genetics, Rift Valley fever virus immunology, Sheep, Viral Vaccines genetics, Livestock virology, Newcastle disease virus genetics, Newcastle disease virus immunology, Vaccination methods, Viral Vaccines immunology
- Abstract
Newcastle disease virus (NDV) is an avian virus that is being evaluated as a vaccine vector for the delivery of foreign genes in mammals. The use of NDV as a vaccine vector in these species offers two major advantages. First, NDV is highly attenuated in mammals, rendering its use inherently safe. Second, mammals lack pre-existing NDV immunity, which minimizes the risk of vaccination failure. NDV-vector vaccines are generally administered to mammals via the respiratory route. We recently showed that intramuscular vaccination with NDV-based Rift Valley fever virus (RVFV) vaccines provides complete protection in mice and induces neutralizing antibodies in sheep and cattle, the main target species of RVFV. Here, we discuss the use of NDV as a vaccine vector for applications in mammalian livestock with an emphasis on the vaccination route. We also report the results of novel experiments that underscore our notion that vaccination via a parenteral route is more effective than immunization via the respiratory route., (© 2011 Landes Bioscience)
- Published
- 2011
- Full Text
- View/download PDF
33. Interventions against West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus: where are we?
- Author
-
Kortekaas J, Ergönül O, and Moormann RJ
- Subjects
- Communicable Diseases, Emerging prevention & control, Disease Outbreaks prevention & control, Humans, Protein Subunits, Vaccines, Synthetic immunology, Antiviral Agents therapeutic use, Hemorrhagic Fever, Crimean prevention & control, Rift Valley Fever prevention & control, Viral Vaccines immunology, West Nile Fever prevention & control
- Abstract
ARBO-ZOONET is an international network financed by the European Commission's seventh framework program. The major goal of this initiative is capacity building for the control of emerging viral vector-borne zoonotic diseases, with a clear focus on West Nile virus, Rift Valley fever virus, and Crimean-Congo hemorrhagic fever virus. To evaluate the status quo of control measures against these viruses, an ARBO-ZOONET meeting was held in Istanbul, Turkey, from 19 to 20 November 2009. The symposium consisted of three themes: (1) vaccines: new and existing ones; (2) antivirals: existing and new developments; and (3) antivector vaccines. In addition, a satellite workshop was held on epidemiology and diagnosis. The meeting brought together foremost international experts on the subjects from both within and without the ARBO-ZOONET consortium. This report highlights selected results from these presentations and major conclusions that emanated from the discussions held.
- Published
- 2010
- Full Text
- View/download PDF
34. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector.
- Author
-
Kortekaas J, de Boer SM, Kant J, Vloet RP, Antonis AF, and Moormann RJ
- Subjects
- Animals, Female, Mice, Mice, Inbred BALB C, Rift Valley Fever prevention & control, Rift Valley fever virus pathogenicity, Sheep, Newcastle disease virus immunology, Rift Valley Fever immunology, Rift Valley fever virus immunology, Viral Vaccines immunology
- Abstract
Rift Valley fever virus (RVFV) causes recurrent large outbreaks among humans and livestock. Although the virus is currently confined to the African continent and the Arabian Peninsula, there is a growing concern for RVFV incursions into countries with immunologically naïve populations. The RVFV structural glycoproteins Gn and Gc are preferred targets in the development of subunit vaccines that can be used to control future outbreaks. We here report the production of Gn and Gc by a recombinant vaccine strain of the avian paramyxovirus Newcastle disease virus (NDV) and demonstrate that intramuscular vaccination with this experimental NDV-based vector vaccine provides complete protection in mice. We also demonstrate that a single intramuscular vaccination of lambs, the main target species of RVFV, is sufficient to elicit a neutralizing antibody response.
- Published
- 2010
- Full Text
- View/download PDF
35. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus.
- Author
-
Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, Vloet RP, de Wit AA, Peeters BP, and Moormann RJ
- Subjects
- Administration, Intranasal, Animals, Cattle, Injections, Intramuscular, Rift Valley fever virus genetics, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Viral Vaccines administration & dosage, Viral Vaccines genetics, Antibodies, Neutralizing blood, Antibodies, Viral blood, Genetic Vectors, Newcastle disease virus genetics, Rift Valley fever virus immunology, Viral Vaccines immunology
- Abstract
In the past decade, the use of Newcastle disease virus (NDV) as a vaccine vector for the prevention of economically important livestock diseases as well as for human diseases has been extensively explored. In this study, we have constructed a recombinant NDV vaccine virus, named NDFL-Gn, that produces the Rift Valley fever virus (RVFV) Gn glycoprotein. Calves were immunized via either the intranasal route or the intramuscular route. Delivery via the intranasal route elicited no detectable antibody responses, whereas delivery via the intramuscular route elicited antibodies against both NDV and the Gn protein. The RVFV-neutralizing activity of the antisera from intramuscularly vaccinated calves was demonstrated, suggesting that NDV is a promising vaccine vector for the prevention of RVF in calves., (Copyright 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
36. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge.
- Author
-
de Boer SM, Kortekaas J, Antonis AF, Kant J, van Oploo JL, Rottier PJ, Moormann RJ, and Bosch BJ
- Subjects
- Animals, Antibodies, Viral blood, Cell Line, Drosophila, Enzyme-Linked Immunosorbent Assay, Female, Humans, Mice, Mice, Inbred BALB C, Rift Valley Fever immunology, Survival Analysis, Vaccines, Subunit immunology, Vaccines, Virosome immunology, Viral Envelope Proteins immunology, Rift Valley Fever prevention & control, Rift Valley fever virus immunology, Viral Vaccines immunology
- Abstract
Rift Valley fever virus (RVFV) is an emerging mosquito-borne virus causing significant morbidity and mortality in livestock and humans. Rift Valley fever is endemic in Africa, but also outside this continent outbreaks have been reported. Here we report the evaluation of two vaccine candidates based on the viral Gn and Gc envelope glycoproteins, both produced in a Drosophila insect cell expression system. Virus-like particles (VLPs) were generated by merely expressing the Gn and Gc glycoproteins. In addition, a soluble form of the Gn ectodomain was expressed and affinity-purified from the insect cell culture supernatant. Both vaccine candidates fully protected mice from a lethal challenge with RVFV. Importantly, absence of the nucleocapsid protein in either vaccine candidate facilitates the differentiation between infected and vaccinated animals using a commercial recombinant nucleocapsid protein-based indirect ELISA., (Copyright 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
37. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology.
- Author
-
Kimman TG, Cornelissen LA, Moormann RJ, Rebel JM, and Stockhofe-Zurwieden N
- Subjects
- Animals, Porcine Reproductive and Respiratory Syndrome immunology, Porcine respiratory and reproductive syndrome virus pathogenicity, Porcine respiratory and reproductive syndrome virus physiology, Swine, Porcine Reproductive and Respiratory Syndrome prevention & control, Porcine respiratory and reproductive syndrome virus immunology, Viral Vaccines immunology
- Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) continues to be a threat for the pig industry. Vaccines have been developed, but these failed to provide sustainable disease control, in particular against genetically unrelated strains. Here we give an overview of current knowledge and gaps in our knowledge that may be relevant for the development of a future generation of more effective vaccines. PRRSV replicates in cells of the monocyte/macrophage lineage, induces apoptosis and necrosis, interferes with the induction of a proinflammatory response, only slowly induces a specific antiviral response, and may cause persistent infections. The virus appears to use several evasion strategies to circumvent both innate and acquired immunity, including interference with antigen presentation, antibody-mediated enhancement, reduced cell surface expression of viral proteins, and shielding of neutralizing epitopes. In particular the downregulation of type I interferon-alpha production appears to interfere with the induction of acquired immunity. Current vaccines are ineffective because they suffer both from the immune evasion strategies of the virus and the antigenic heterogeneity of field strains. Future vaccines therefore must "uncouple" the immune evasion and apoptogenic/necrotic properties of the virus from its immunogenic properties, and they should induce a broad immune response covering the plasticity of its major antigenic sites. Alternatively, the composition of the vaccine should be changed regularly to reflect presently and locally circulating strains. Preferably new vaccines should also allow discriminating infected from vaccinated pigs to support a virus elimination strategy. Challenges in vaccine development are the incompletely known mechanisms of immune evasion and immunity, lack of knowledge of viral sequences that are responsible for the pathogenic and immunosuppressive properties of the virus, lack of knowledge of the forces that drive antigenic heterogeneity and its consequences for immunogenicity, and a viral genome that is relatively intolerant for subtle changes at functional sites.
- Published
- 2009
- Full Text
- View/download PDF
38. Dimerization of glycoprotein E(rns) of classical swine fever virus is not essential for viral replication and infection.
- Author
-
van Gennip HG, Hesselink AT, Moormann RJ, and Hulst MM
- Subjects
- Animals, Cell Line, Classical Swine Fever Virus genetics, Classical Swine Fever Virus pathogenicity, DNA Primers, Dimerization, Kidney, Molecular Sequence Data, Swine, Viral Envelope Proteins genetics, Viral Proteins isolation & purification, Viral Proteins metabolism, Classical Swine Fever virology, Classical Swine Fever Virus physiology, Viral Envelope Proteins metabolism, Virus Replication physiology
- Abstract
The pestivirus glycoprotein E(rns), a ribonuclease, is expressed on the surface of virions and in infected cells as a disulfide-linked homodimer. E(rns) is involved in the infection process and its RNase activity is probably involved in viral replication and pathogenesis. The most C-terminal cysteine residue forms an intermolecular disulfide bond with another E(rns) monomer, resulting in an E(rns) dimer. To study the function of dimerisation of E(rns) for viral replication, the cysteine residue at amino acid position 438 was mutated into a serine residue. The mutated C438S gene was cloned into a vector containing an infectious cDNA copy of the CSFV C-strain genome. Using reverse genetics, a mutant virus was generated that only expressed monomeric E(rns), confirming that Cys 438 is essential for homo-dimerization. Characterization of this mutant virus and of a baculovirus-expressed C438S mutant protein indicated that the loss of the dimeric state of E(rns) reduced the affinity of binding of virions and E(rns) to heparan sulphate (HS), the receptor for E(rns) on the cell surface of SK6 cells. This suggests that interaction of virus-bound E(rns) homodimers with membrane associated HS may be a joined action of the two HS-binding domains (one in each monomer) present in the homodimer.
- Published
- 2005
- Full Text
- View/download PDF
39. Determinants of virulence of classical swine fever virus strain Brescia.
- Author
-
Van Gennip HG, Vlot AC, Hulst MM, De Smit AJ, and Moormann RJ
- Subjects
- Amino Acid Sequence, Animals, Cell Line, Classical Swine Fever Virus classification, Classical Swine Fever Virus genetics, Recombination, Genetic, Sequence Alignment, Swine, Virulence, Classical Swine Fever virology, Classical Swine Fever Virus metabolism, Classical Swine Fever Virus pathogenicity, Heparitin Sulfate metabolism, Mutation, Viral Envelope Proteins genetics
- Abstract
Two related classical swine fever virus (CSFV) strain Brescia clones were isolated from blood samples from an infected pig. Virus C1.1.1 is a cell-adapted avirulent variant, whereas CoBrB is a virulent variant. Sequence analysis revealed 29 nucleic acid mutations in C1.1.1, resulting in 9 amino acid substitutions compared to the sequence of CoBrB (476)R. Using reverse genetics, parts of the genomes of these viruses, which contain differences that lead to amino acid changes, were exchanged. Animal experiments with chimeric viruses derived from C1.1.1 and CoBrB (476)R showed that a combination of amino acid changes in the structural and nonstructural regions reduced the virulence of CSFV in pigs. Moreover, the presence of a Leu at position 710 in structural envelope protein E2 seemed to be an important factor in the virulence of the virus. Changing the Leu at position 710 in the CoBrB (476)S variant into a His residue did not affect virulence. However, the (710)His in the C1.1.1/CoBrB virus, together with adaptive mutations (276)R, (476)R, and (477)I in E(rns), resulted in reduced virulence in pigs. These results indicated that mutations in E(rns) and E2 alone do not determine virulence in pigs. The results of in vitro experiments suggested that a high affinity for heparan sulfate of C1.1.1 E(rns) may reduce the spread of the C1.1.1/CoBrB virus in pigs and together with the altered surface structure of E2 caused by the (710)L-->H mutation may result in a less efficient infection of specific target cells in pigs. Both these features contributed to the attenuation of the C1.1.1/CoBrB virus in vivo.
- Published
- 2004
- Full Text
- View/download PDF
40. Effects of mutations in the VP2/VP4 cleavage site of Swine vesicular disease virus on RNA encapsidation and viral infectivity.
- Author
-
Rebel JM, Leendertse CH, Dekker A, and Moormann RJ
- Subjects
- Capsid Proteins chemistry, Electroporation, Mutation, RNA, Viral analysis, Virus Replication, Capsid Proteins metabolism, Enterovirus B, Human physiology, RNA, Viral physiology, Virus Assembly
- Abstract
We studied VP0 cleavage of Swine vesicular disease virus (SVDV), a member of the Picornaviridae using a full-length cDNA copy of the Dutch SVDV isolate. The influences of mutations, introduced at the cleavage site of SVDV, on VP0 cleavage, RNA encapsidation and viral infection were studied. Double mutations at asparagine (VP0 aa 69) and serine (VP0 aa 70) resulted in no cleavage of VP0 and 100% inhibition of virus production. Mutation of the asparagine into threonine or phenylalanine resulted in a low amount of cleaved VP0 and infectious virus was found. After passage of this mutated virus VP0 cleavage became more efficient and the growth rate of the virus became similar to wild-type SVDV. The passaged virus had mutated at the asparagine site; the threonine had changed into an alanine and the phenylalanine into a cysteine. When the serine was mutated no maturation cleavage was observed and no infectious virus could be derived. All the mutations resulted in RNA encapsidation. We conclude that in the case of SVDV the cleavage site between VP2 and VP4 is essential for the formation of infectious virus which is comparable to poliovirus. The serine of the VP0 site was more important than the asparagine in this respect.
- Published
- 2003
- Full Text
- View/download PDF
41. Influence of maternal antibodies on efficacy of a subunit vaccine: transmission of classical swine fever virus between pigs vaccinated at 2 weeks of age.
- Author
-
Klinkenberg D, Moormann RJ, de Smit AJ, Bouma A, and de Jong MC
- Subjects
- Animals, Animals, Newborn, Antibodies, Viral blood, Classical Swine Fever prevention & control, Female, Pregnancy, Time Factors, Vaccines, Subunit pharmacology, Classical Swine Fever immunology, Classical Swine Fever transmission, Classical Swine Fever Virus immunology, Immunity, Maternally-Acquired, Viral Vaccines pharmacology
- Abstract
This study shows the effectiveness of vaccination with an E2 subunit vaccine against classical swine fever (CSF) in 2-week-old piglets. Half of the piglets were carrying maternally derived antibodies (MDAs) at the time of vaccination. Three and 6 months later, antibody levels were compared between the two treatments. Moreover, reduction of virus transmission was investigated at 3 and 6 months by doing transmission experiments. The vaccine was found to be capable of reducing virus transmission significantly at both time intervals. Maternal immunity reduced vaccination-induced antibody levels after 3 and 6 months and possibly led to a less effective protection against virus transmission after 6 months.
- Published
- 2002
- Full Text
- View/download PDF
42. Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.
- Author
-
van Gennip HG, Bouma A, van Rijn PA, Widjojoatmodjo MN, and Moormann RJ
- Subjects
- Animals, Base Sequence, Cell Line, Classical Swine Fever immunology, DNA, Viral genetics, Genes, Viral, Genetic Complementation Test, Genetic Markers, Injections, Intradermal, Mutation, Sequence Deletion, Swine, Viral Envelope Proteins genetics, Viral Envelope Proteins immunology, Viral Vaccines administration & dosage, Classical Swine Fever prevention & control, Classical Swine Fever Virus genetics, Classical Swine Fever Virus immunology, Viral Vaccines genetics
- Abstract
Three mutants with deletions in the E2 gene of the infectious DNA copy of the classical swine fever virus (CSFV) strain-C were constructed: one missing the B/C domain of CSFV-E2 between amino acids (aa) 693 and 746, one missing the A domain between aa 800 and 864, and one missing the complete E2 between aa 689 and 1062. All three CSFV-E2 deletion mutants were unable to generate viable virus, indicating that each of the antigenic domains of E2 is essential for viability of CSFV. To rescue the CSFV-E2 deletion mutants SK6 cell lines constitutively expressing glycoprotein E2 of CSFV were generated. The rescued viruses infected and replicated in SK6 cells as demonstrated by expression of viral proteins, but this primary infection did not result in reproduction of infectious virus. Thus, these E2 complemented viruses are considered non-transmissible. In previous experiments, we showed that simultaneous injection of E(rns) complemented virus (Flc23) via intradermal (ID), intramuscular (IM) or intranasal (IN) routes conferred protection to pigs against a lethal challenge with CSFV [J. Virol. 74 (2000) 2973]. Here, we evaluate different routes of application (ID, IM or IN) with E(rns) complemented virus Flc23 in order to find the best route for complemented CSFVs. Intradermal injection with Flc23 protected pigs against a lethal CSFV challenge, whereas intramuscular injection induced partial protection, and intranasal injection did not mediate a protective immune response in pigs at all. We used the intradermal route of vaccination to test the E2 complemented viruses. Vaccination of pigs via the intradermal route with the E2 complemented CSFVs also resulted in the induction of antibodies and in (partial) protection against CSFV challenge. Pigs vaccinated with E2 complemented virus Flc4 (deletion B/C domain) survived a lethal CSFV challenge, whereas partial protection was induced in pigs vaccinated with Flc47 (deletion E2) or Flc48 (deletion A domain) E2 complemented viruses. Serological data demonstrate that these E2 complemented mutant viruses are, in combination with well known diagnostic tests based on E2, potential marker vaccines for CSF.
- Published
- 2002
- Full Text
- View/download PDF
43. [Vaccination against foot and mouth disease: a biotechnical approach?].
- Author
-
Moormann RJ
- Subjects
- Animals, Safety, Vaccination veterinary, Vaccines, Marker, Foot-and-Mouth Disease prevention & control, Foot-and-Mouth Disease Virus immunology, Immunization, Passive veterinary, Ruminants, Viral Vaccines
- Abstract
Described is how through a biotechnical approach a FMD 'marker' vaccine and matching diagnostic test could be developed which makes it possible to control FMD safety and effectively. Much research is still necessary but important in this is that the European Union supports these developments.
- Published
- 2001
44. Interaction of classical swine fever virus with membrane-associated heparan sulfate: role for virus replication in vivo and virulence.
- Author
-
Hulst MM, van Gennip HG, Vlot AC, Schooten E, de Smit AJ, and Moormann RJ
- Subjects
- Animals, Arginine genetics, Cell Membrane metabolism, Cells, Cultured, Classical Swine Fever Virus pathogenicity, Concanavalin A, Dose-Response Relationship, Drug, Heparin pharmacology, Mutation, Recombinant Proteins metabolism, Serine genetics, Specific Pathogen-Free Organisms, Swine, Viral Envelope Proteins biosynthesis, Viral Envelope Proteins genetics, Viral Envelope Proteins metabolism, Virulence drug effects, Virus Replication drug effects, Classical Swine Fever virology, Classical Swine Fever Virus metabolism, Heparitin Sulfate metabolism
- Abstract
Passage of native classical swine fever virus (CSFV) in cultured swine kidney cells (SK6 cells) selects virus variants that attach to the surface of cells by interaction with membrane-associated heparan sulfate (HS). A Ser-to-Arg change in the C terminus of envelope glycoprotein E(rns) (amino acid 476 in the open reading frame of CSFV) is responsible for selection of these HS-binding virus variants (M. M. Hulst, H. G. P. van Gennip, and R. J. M. Moormann, J. Virol. 74:9553-9561, 2000). In this investigation we studied the role of binding of CSFV to HS in vivo. Using reverse genetics, an HS-independent recombinant virus (S-ST virus) with Ser(476) and an HS-dependent recombinant virus (S-RT virus) with Arg(476) were constructed. Animal experiments indicated that this adaptive Ser-to-Arg mutation had no effect on the virulence of CSFV. Analysis of viruses reisolated from pigs infected with these recombinant viruses indicated that replication in vivo introduced no mutations in the genes of the envelope proteins E(rns), E1, and E2. However, the blood of one of the three pigs infected with the S-RT virus contained also a low level of virus particles that, when grown under a methylcellulose overlay, produced relative large plaques, characteristic of an HS-independent virus. Sequence analysis of such a large-plaque phenotype showed that Arg(476) was mutated back to Ser(476). Removal of HS from the cell surface and addition of heparin to the medium inhibited infection of cultured (SK6) and primary swine kidney cells with S-ST virus reisolated from pigs by about 70% whereas infection with the administered S-ST recombinant virus produced in SK6 cells was not affected. Furthermore, E(rns) S-ST protein, produced in insect cells, could bind to immobilized heparin and to HS chains on the surface of SK6 cells. These results indicated that S-ST virus generated in pigs is able to infect cells by an HS-dependent mechanism. Binding of concanavalin A (ConA) to virus particles stimulated the infection of SK6 cells with S-ST virus produced in these cells by 12-fold; in contrast, ConA stimulated infection with S-ST virus generated in pigs no more than 3-fold. This suggests that the surface properties of S-ST virus reisolated from pigs are distinct from those of S-ST virus produced in cell culture. We postulate that due to these surface properties, in vivo-generated CSFV is able to infect cells by an HS-dependent mechanism. Infection studies with the HS-dependent S-RT virus, however, indicated that interaction with HS did not mediate infection of lung macrophages, indicating that alternative receptors are also involved in the attachment of CSFV to cells.
- Published
- 2001
- Full Text
- View/download PDF
45. Secretory pathway limits the enhanced expression of classical swine fever virus E2 glycoprotein in insect cells.
- Author
-
van Oers MM, Thomas AA, Moormann RJ, and Vlak JM
- Subjects
- 3' Untranslated Regions, Amino Acid Sequence, Animals, Base Sequence, Electrophoresis, Polyacrylamide Gel, Enzyme-Linked Immunosorbent Assay, Genetic Vectors, Glycosylation, Immunoblotting, RNA, Messenger analysis, Recombinant Proteins biosynthesis, Simian virus 40 genetics, Baculoviridae genetics, Gene Expression, Spodoptera metabolism, Viral Envelope Proteins genetics, Viral Envelope Proteins metabolism
- Abstract
The 3' untranslated region (UTR) is an important element that determines the level of recombinant protein expression via baculovirus vectors. Previous work using chloramphenicol acetyl transferase as reporter has shown that p10-promoter based baculovirus vectors with the authentic p10 3' UTR resulted in higher expression levels than vectors carrying an SV40 early terminator, as part of a lacZ selection cassette. To examine whether a similar increase in expression levels could be obtained for baculovirus-expressed glycoproteins, the classical swine fever virus E2 antigen was used as a model. With the authentic p10 3' UTR higher levels of E2 transcript were found than in the presence of the SV40 terminator. This higher number of transcripts was accompanied by elevated levels of intracellular, non-glycosylated E2 protein. However, the levels of intracellular glycosylated forms of E2 and of extracellular E2 were similar for both type of terminators. These results show that translation of the recombinant mRNA is not the rate limiting step in the expression of glycoproteins, but the downstream processing and secretion of the translation products.
- Published
- 2001
- Full Text
- View/download PDF
46. Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination.
- Author
-
de Smit AJ, Bouma A, de Kluijver EP, Terpstra C, and Moormann RJ
- Subjects
- Animals, Antibodies, Viral blood, Classical Swine Fever prevention & control, Classical Swine Fever transmission, Classical Swine Fever Virus pathogenicity, Fluorescent Antibody Technique, Direct veterinary, Leukocyte Count veterinary, Neutralization Tests veterinary, Random Allocation, Swine, Thrombocytopenia veterinary, Time Factors, Viremia veterinary, Classical Swine Fever immunology, Classical Swine Fever Virus immunology, Vaccination veterinary, Viral Envelope Proteins immunology
- Abstract
The period during which pigs are protected after vaccination is important for the successful usage of a marker vaccine against classical swine fever virus (CSFV) in an eradication programme. In four animal experiments with different vaccination-challenge intervals we determined the duration of protection of an E2 subunit marker vaccine in pigs after a single vaccination. Unvaccinated pigs were included in each group to detect transmission of the challenge virus. Three groups of six pigs were vaccinated once and subsequently inoculated with the virulent CSFV strain Brescia after a vaccination-challenge interval of 3, 51/2, 6 or 13 months. All vaccinated pigs, 16 out of 18, with neutralising antibodies against CSFV at the moment of challenge, 3, 51/2, 6 or 13 months later, survived, whereas unvaccinated control pigs died from acute CSF or were killed being moribund. A proportion of the vaccinated pigs did however develop fever or cytopenia after challenge and two vaccinated pigs were viremic after challenge. Virus transmission of vaccinated and challenged pigs to unvaccinated sentinel pigs did not occur in groups of pigs which were challenged 3 or 6 months after a single vaccination. Two out of eight vaccinated pigs that were found negative for CSFV neutralising antibody at 13 months after vaccination died after subsequent challenge. The findings in this study demonstrate that pigs can be protected against a lethal challenge of CSFV for up to 13 months after a single vaccination with an E2 subunit marker vaccine.
- Published
- 2001
- Full Text
- View/download PDF
47. Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs.
- Author
-
de Smit AJ, Bouma A, van Gennip HG, de Kluijver EP, and Moormann RJ
- Subjects
- Animals, Antibodies, Viral biosynthesis, Chimera genetics, Chimera immunology, Classical Swine Fever immunology, Classical Swine Fever transmission, Classical Swine Fever Virus pathogenicity, Genetic Markers, Swine, Vaccination veterinary, Vaccines, Synthetic pharmacology, Viral Vaccines pharmacology, Virulence, Classical Swine Fever prevention & control, Classical Swine Fever Virus genetics, Classical Swine Fever Virus immunology
- Abstract
Two live recombinant vaccines (Flc9 and Flc11) against classical swine fever (CSF) were evaluated for their capacity to reduce transmission of virulent CSF virus (CSFV) among vaccinated pigs. In Flc9 the 5' terminal half of the E2 gene of the C-strain, a CSFV vaccine strain, was exchanged with the homologous gene of the bovine viral diarrhoea virus (BVDV) strain 5250, the E(rns) gene was exchanged likewise in the chimeric Flc11 virus. Both recombinant vaccines induce an antibody response in pigs that can be distinguished from that induced after a wild-type CSFV infection. Four experiments were performed to estimate the reproduction ratio R after different vaccination-challenge intervals. Each group consisted of ten pigs [specified pathogen free (SPF) pigs or conventional pigs] that were vaccinated once, intramuscularly, either with Flc9 or Flc11 virus or that were not vaccinated. Vaccinated and susceptible pigs were challenged intranasally with the virulent CSFV strain Brescia or Behring, 1, 2 or 4 weeks after vaccination. Whether contact-pigs became infected was determined using a CSFV specific E2 (Flc9) or E(rns) (FLc11) antibody ELISA. In the unvaccinated control groups, virus secretion started from day 2 to 4 after inoculation and all contact pigs became infected. Contact pigs became infected in the group of pigs (SPF or conventional) vaccinated once with Flc9 virus and challenged 1-, 2- or 4-weeks later. The estimates of the R in the groups challenged at 1-, 2- and 4-weeks after vaccination were 0.38, 0 and 0.75, respectively. Contact infected pigs were not detected (R=0) in any of the groups of pigs, vaccinated with Flc11, only SPF pigs were used. In order to achieve a statistical significance of R within the vaccinated groups each of the experiments has to be repeated at least once. The R of pigs vaccinated with Flc11 virus and challenged at 1- or 2-weeks after vaccination was however significantly lower that the reproduction ratio of the unvaccinated groups (P=0.013). The R of pigs vaccinated with Flc9 virus and challenged at 1 (conventional pigs) or 2 weeks (SPF pigs) after vaccination was significantly lower that the reproduction ratio of the unvaccinated groups (P=0.013). In conclusion, both chimeric viruses Flc9 and Flc11 provided good clinical protection against a challenge with virulent CSFV at 1 or 2 weeks after vaccination. Further experiments should be carried out to study more aspects of the efficacy of these recombinant viruses before they can be used as a marker vaccine under field circumstances.
- Published
- 2001
- Full Text
- View/download PDF
48. Erns protein of pestiviruses.
- Author
-
Hulst MM and Moormann RJ
- Subjects
- Amino Acid Sequence, Chromatography, Affinity, Classical Swine Fever Virus pathogenicity, Classical Swine Fever Virus physiology, Molecular Sequence Data, Ribonucleases chemistry, Ribonucleases genetics, Sequence Homology, Amino Acid, Viral Envelope Proteins chemistry, Viral Envelope Proteins genetics, Virulence, Classical Swine Fever Virus metabolism, Ribonucleases metabolism, Viral Envelope Proteins metabolism
- Published
- 2001
- Full Text
- View/download PDF
49. Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response.
- Author
-
van Gennip HG, van Rijn PA, Widjojoatmodjo MN, de Smit AJ, and Moormann RJ
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, Cattle, Chimera genetics, Chimera immunology, Classical Swine Fever immunology, Classical Swine Fever prevention & control, Classical Swine Fever Virus genetics, Cloning, Molecular, DNA Primers genetics, DNA, Complementary genetics, DNA, Viral genetics, Diarrhea Viruses, Bovine Viral genetics, Genes, Viral, Molecular Sequence Data, Sequence Homology, Amino Acid, Swine, Vaccines, Attenuated genetics, Vaccines, Attenuated immunology, Vaccines, Synthetic genetics, Vaccines, Synthetic immunology, Viral Envelope Proteins genetics, Viral Vaccines genetics, Viral Vaccines immunology, Antibodies, Viral biosynthesis, Classical Swine Fever Virus immunology, Diarrhea Viruses, Bovine Viral immunology, Viral Envelope Proteins immunology
- Abstract
Three chimeric classical swine fever virus (CSFV)/bovine viral diarrhoea virus (BVDV) full-length DNA copies were constructed, based on the infectious DNA copy of the CSFV vaccine strain C. The antigenic region of E2 and/or the complete E(RNS) gene were replaced by the analogous sequence of BVDV II strain 5250. Viable chimeric virus Flc11, in which E(RNS) was replaced, was directly recovered from supernatant of SK6.T7 cells transfected with full-length DNA. Viable chimeric virus Flc9, in which E2 was replaced, resulted in recovery of virus only when SK6.T7 transfected cells were maintained for several passages. However, no virus could be recovered after replacement of both E(RNS) and E2, even after 10 cell passages. Both Flc9 and Flc11 grow in swine kidney cells (SK6), stably maintain their heterologous BVDV sequences and, as assessed by monoclonal antibody typing and radio-immunoprecipitation assays, express their heterologous proteins. Flc9 showed a slower growth rate on SK6 cells than Flc11 and wild-type Flc2 virus. Replacement of E(RNS) or E2 of C-strain-based chimeric viruses did not alter cell tropism compared to wild-type C-strain virus for SK6 and FBE cells. Both Flc9 and Flc11 induced E2 or E(RNS) antibodies, which could be discriminated from those induced after wild-type virus infection, even after repeated vaccination. Furthermore, pigs were completely protected against a lethal CSFV challenge. These results indicate the feasibility of introduction of marker antigens in a live-attenuated marker C-strain vaccine for CSFV.
- Published
- 2000
- Full Text
- View/download PDF
50. Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E(rns).
- Author
-
Hulst MM, van Gennip HG, and Moormann RJ
- Subjects
- Amino Acid Sequence, Animals, Cattle, Cells, Cultured, Glycosaminoglycans physiology, Heparin pharmacology, Molecular Sequence Data, Recombinant Proteins metabolism, Structure-Activity Relationship, Swine, Viral Envelope Proteins chemistry, Classical Swine Fever Virus physiology, Heparitin Sulfate physiology, Kidney virology, Viral Envelope Proteins physiology
- Abstract
Infection of cells with Classical swine fever virus (CSFV) is mediated by the interaction of envelope glycoprotein E(rns) and E2 with the cell surface. In this report we studied the role of the cell surface glycoaminoglycans (GAGs), chondroitin sulfates A, B, and C (CS-A, -B, and -C), and heparan sulfate (HS) in the initial binding of CSFV strain Brescia to cells. Removal of HS from the surface of swine kidney cells (SK6) by heparinase I treatment almost completely abolished infection of these cells with virus that was extensively passaged in swine kidney cells before it was cloned (clone C1.1.1). Infection with C1.1.1 was inhibited completely by heparin (a GAG chemically related to HS but sulfated to a higher extent) and by dextran sulfate (an artificial highly sulfated polysaccharide), whereas HS and CS-A, -B, and -C were unable to inhibit infection. Bound C1.1.1 virus particles were released from the cell surface by treatment with heparin. Furthermore, C1.1.1 virus particles and CSFV E(rns) purified from insect cells bound to immobilized heparin, whereas purified CSFV E2 did not. These results indicate that initial binding of this virus clone is accomplished by the interaction of E(rns) with cell surface HS. In contrast, infection of SK6 cells with virus clones isolated from the blood of an infected pig and minimally passaged in SK6 cells was not affected by heparinase I treatment of cells and the addition of heparin to the medium. However, after one additional round of amplification in SK6 cells, infection with these virus clones was affected by heparinase I treatment and heparin. Sequence analysis of the E(rns) genes of these virus clones before and after amplification in SK6 cells showed that passage in SK6 cells resulted in a change of an Ser residue to an Arg residue in the C terminus of E(rns) (amino acid 476 in the polyprotein of CSFV). Replacement of the E(rns) gene of an infectious DNA copy of C1.1.1 with the E(rns) genes of these virus variants proved that acquisition of this Arg was sufficient to alter an HS-independent virus to a virus that uses HS as an E(rns) receptor.
- Published
- 2000
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.